At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 67 enrolled
Drug / intervention
imatinib mesylate +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Stage Phase II, Multi-centre, Open Label Study of Imatinib in Combination With Pioglitazone, Etoricoxib, Dexamethasone and Low-dose Treosulfane for Anti-inflammatory and Angiostatic Treatment in Patients With Hormone-refractory Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating imatinib mesylate, Treosulfane, and 3 other interventions for Prostate Cancer. Completed, enrolled 67 participants across 10 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy, tolerability and safety of a multi-targeted therapy in patients with hormone-refractory prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2007
Enrollment StartFeb 2007
Primary CompletionJun 2015
Study CompletionAug 2015
TodayJul 2026
First PostedJan 29, 2007
Enrollment StartFeb 1, 2007
Primary CompletionJun 1, 2015
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 19.4 years ago
Interventions
imatinib mesylatedrug
Treosulfanedrug
etoricoxibdrug
pioglitazonedrug
dexamethasonedrug